Boston Scientific Balance Sheet Health
Financial Health criteria checks 5/6
Boston Scientific has a total shareholder equity of $20.6B and total debt of $10.6B, which brings its debt-to-equity ratio to 51.3%. Its total assets and total liabilities are $37.1B and $16.5B respectively. Boston Scientific's EBIT is $2.7B making its interest coverage ratio 10.7. It has cash and short-term investments of $2.9B.
Key information
51.3%
Debt to equity ratio
US$10.57b
Debt
| Interest coverage ratio | 10.7x |
| Cash | US$2.91b |
| Equity | US$20.61b |
| Total liabilities | US$16.50b |
| Total assets | US$37.11b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BSX's short term assets ($9.0B) exceed its short term liabilities ($5.6B).
Long Term Liabilities: BSX's short term assets ($9.0B) do not cover its long term liabilities ($10.9B).
Debt to Equity History and Analysis
Debt Level: BSX's net debt to equity ratio (37.1%) is considered satisfactory.
Reducing Debt: BSX's debt to equity ratio has reduced from 101.2% to 51.3% over the past 5 years.
Debt Coverage: BSX's debt is well covered by operating cash flow (24.9%).
Interest Coverage: BSX's interest payments on its debt are well covered by EBIT (10.7x coverage).